Texas Center for Cancer Nanomedicine

德克萨斯癌症纳米医学中心

• 批准号: 8323397
• 负责人: MAURO FERRARI
• 金额: $ 253.85万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8323397
• 关键词: Cancer Center; Texas; nanomedicine

The University of Texas Health Science Center at Houston (UTHSC-H), The University of Texas M.D. Anderson Cancer Center, Rice University and Albert Einstein College of Medicine have joined forces to form the Texas Center for Cancer Nanomedicine (TCCN). The TCCN brings together a multi-disciplinary, internationally recognized team of investigators to develop and translate nanotechnology-enabled innovation for improving the traditionally dismal outcome of ovarian and pancreatic cancers. The main research focus areas of the TCCN are: Multifunctional Nano-Therapeutics and Post-Therapy Monitoring Tools (Area 2 of the CCNE RFA), and Devices and Techniques for Cancer Prevention and Control (Area 3). By natural synergies of the underlying nano-platforms, the TCCN's investigations in focus areas 2 and 3 automatically provide a cadre of approaches for Area 1: Early Diagnosis Using In-Vitro Assays and Devices and In-Vivo Imaging Techniques. The TCCN has four projects and three cores. Projects 1 and 2 directly address ovarian cancer, and Projects 3 and 4 directly address pancreatic cancer. In each oncology focus area, one project involves multifunctional nanoplatforms for the delivery of bioactive agents to the tumors (Project 1- ovarian and Project 3- pancreatic), and the other, targeting approaches to the cancer-associated vascular endothelia (Project 2- ovarian and Project 4- pancreatic), for imaging and therapy. Both adenocarcinoma (Project 3) and endocrine pancreatic malignancies (Project 4) are considered in the TCCN. All Projects integrate fundamental investigations in cancer biology, nanotechnology platform development, and pharmaceutical sciences, albeit to different degrees. The cores are the Biomathematics Core, Targeting Core and Nanoengineering Core. All projects and Cores integrate with each other through the sharing of research results and nanotechnology platforms. This integration allows the TCCN to achieve clinical translation of its research breakthroughs, and aggressively manage the risks that are naturally associated with any highly innovative program at a rapid pace. To fuel translation to the clinic, several TCCN investigators have successfully developed spin-off companies based upon their research. Collectively, with a combination of synergistic projects supported by cores that provide services to each project and a track record of successful bench-to-bedside translation, the TCCN is uniquely positioned to bring forth highly effective nanotechnology platforms for prevention, therapy and monitoring of ovarian and pancreatic cancers.

德克萨斯大学休斯顿健康科学中心（UTHSC-H），德克萨斯大学医学博士安德森癌症中心、莱斯大学和阿尔伯特·爱因斯坦医学院联合成立了德克萨斯癌症纳米医学中心（TCCN）。TCCN汇集了一个多学科，国际公认的研究团队，开发和翻译纳米技术创新，以改善卵巢癌和胰腺癌传统上令人沮丧的结果。TCCN的主要研究重点领域是：多功能纳米治疗和治疗后监测工具（CCNE RFA的区域2），以及癌症预防和控制的设备和技术（区域3）。通过基础纳米平台的自然协同作用，TCCN在重点领域2和3的研究自动为领域1提供了一系列方法：使用体外检测和设备以及体内成像技术进行早期诊断。TCCN有四个项目和三个核心。项目1和2直接针对卵巢癌，项目3和4直接针对胰腺癌。在每个肿瘤学重点领域，一个项目涉及多功能纳米平台，用于将生物活性剂输送到肿瘤（项目1-卵巢和项目3-胰腺），另一个项目涉及癌症相关血管内皮的靶向方法（项目2-卵巢和项目4-胰腺），用于成像和治疗。腺癌（项目3）和胰腺内分泌恶性肿瘤（项目4）均在TCCN中考虑。所有项目都整合了癌症生物学，纳米技术平台开发和制药科学的基础研究，尽管程度不同。这些核心是生物数学核心，靶向核心和纳米工程核心。所有项目和核心通过共享研究成果和纳米技术平台相互整合。这种整合使TCCN能够实现其研究突破的临床转化，并以快速的速度积极管理与任何高度创新项目自然相关的风险。为了推动翻译到诊所，几个TCCN研究人员已经成功地开发了基于他们的研究的分拆公司。总的来说，通过为每个项目提供服务的核心支持的协同项目的组合以及成功的实验室到床边翻译的跟踪记录，TCCN具有独特的优势，可以为卵巢癌和胰腺癌的预防，治疗和监测带来高效的纳米技术平台。